Etalocib Explained

Etalocib is a drug candidate that was under development for the treatment of various types of cancer.[1] It acts as a leukotriene B4 receptor antagonist and a PPARγ agonist.[2]

Clinical trials were conducted measuring efficacy for treatment of non-small cell lung cancer and pancreatic cancer and the inflammatory conditions asthma, psoriasis, and ulcerative colitis, but were suspended due to lack of efficacy.[3]

Notes and References

  1. 24346102. 2014. Jänne. P. A.. Randomized, double-blind, phase II trial comparing gemcitabine-cisplatin plus the LTB4 antagonist LY293111 versus gemcitabine-cisplatin plus placebo in first-line non-small-cell lung cancer. Journal of Thoracic Oncology. 9. 1. 126–31. Paz-Ares. L. Oh. Y. Eschbach. C. Hirsh. V. Enas. N. Brail. L. von Pawel. J. 10.1097/JTO.0000000000000037. free.
  2. 19190780. 2008. Adrian. T. E.. The Role of PPARgamma Receptors and Leukotriene B(4) Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer. PPAR Research. 2008. 827096. Hennig. R. Friess. H. Ding. X. 10.1155/2008/827096. 2631651. free.
  3. Web site: Etalocib. Adisinsight. 31 January 2017.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Etalocib".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.